Brief: Acadia Pharmaceuticals Announces Trofinetide New Drug Submission Has Been Accepted For Filing And Priority Review By Health Canada
22/04/2024 14:08
April 22 (Reuters) - ACADIA Pharmaceuticals Inc
ACAD.O :
* ACADIA PHARMACEUTICALS ANNOUNCES TROFINETIDE NEW DRUG
SUBMISSION
FOR TREATMENT OF RETT SYNDROME HAS BEEN ACCEPTED FOR FILING AND
PRIORITY REVIEW BY HEALTH CANADA
Source text for Eikon: ID:nBw5b8Whla
Further company coverage: ACAD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsU.S. STOCKS ON THE MOVE-FactSet, Moderna, Goldman Sachs
U.S. STOCKS ON THE MOVE-Biogen, Incyte, Quantum Cyber
U.S. STOCKS ON THE MOVE-Fortrea, Nuvation Bio, Acadia Pharmaceuticals
Acadia Pharma jumps after EU panel reverses opinion on neurological disorder drug
Brief: Daybu® (Trofinetide) Recommended For Approval In The European Union By CHMP